Cyclic nucleotide phosphodiesterase inhibitors, such as pentoxifylline, have been shown to beneficially influence a large number of inflammatory skin diseases. The biological effects of pentoxifylline on the production of proinflammatory cytokines, leukocyte-endothelial cell adhesion, chemokines and leukocyte-keratinocyte adhesion in skin inflammation are discussed.
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Cyclic nucleotide phosphodiesterases play a key role in the metabolism of cAMP and cGMP. They moderate the intracellular levels of these cyclic nucleotides by increasing their rate of breakdown. It is currently known that the inactivation of cAMP and cGMP can be catalysed by not one, but rather a large number of different cyclic nucleotide phophodiesterases. 1, 2 Recent data show that at least five different isoenzyme families exist and more than 20 distinct enzymes are now recognized and biological reasons for this great diversity are beginning to be unravelled, many of the isoenzymes being differently expressed and regulated in different cell types. 1, 2 Inhibitors of these phosphodiesterases, which elevate intracellular cyclic nucleotide concentrations by preventing the hydrolysis of 3 0 ,5 0 -cyclic nucleotides to 5 0 -nucleotide monophosphates, represent an important group of drugs used in a variety of diseases. Within this group, the xanthine derivatives pentoxifylline (PTX, 1-(5-oxohexyl)-3,7-dimethylxanthine), theophylline and caffeine belong to the nonselective phosphodiesterase inhibitors. They inhibit all four recognized families of cAMP phosphodiesterases as well as the fifth family of phosphodiesterases which is active on cGMP but not cAMP. More recently, more selective inhibitors of different phosphodiesterase isoenzyme families have also been identified and are currently under investigation, 2-6 but there is still little information in the literature regarding the clinical application and biological activities of these selective drugs.
The nonselective inhibitor PTX has been clinically used for decades in the treatment of a variety of microcirculatory disorders, 7 and in dermatology, a great number of skin diseases have also been shown to benefit from treatment with the drug. 8 Recently, attention has also been focused on its potential anti-inflammatory effects. For example, it was found to prevent septic shock in laboratory animals, 9 and to suppress irritant and contact hypersensitivity reactions at a dose of 600 mg q.i.d. 10, 11 In a patient with ulcerating necrobiosis lipoidica, ulcers healed completely within 8 weeks at a dose of 400 mg twice daily. 12 In a patient with polyarteritis nodosa, the livedo reticularis was markedly improved and some of the nodules had resolved after 2 months at a PTX dose of 400 mg t.i.d., and after 8 months, complete remission was achieved. 13 A patient with generalized morphoea noticed softening of the skin lesions after 3 months of treatment with PTX, skin thickness measurements showing an overall reduction in affected skin thickness.
14 In a patient with intractable chronic furunculosis, new lesions ceased appearing after 2 months of treatment at a dose of 400 mg t.i.d. 15 Twenty patients with aphthous stomatitis treated with PTX (400 mg t.i.d.) were also studied monthly for 6 months. No relapses were observed during the course of treatment in 11 patients, while six experienced considerable improvement, and recurrence of the ulcers without symptomatic improvement was observed in only the remaining three patients. 16 In a preliminary, open, placebo-controlled study of 22 psoriasis patients treated with PTX (400 mg t.i.d.) for 28 days, the mean Psoriasis Area and Severity Index (PASI) decreased from 24.2 to 15.3 in the PTX group and from 20.1 to 17.3 in the placebo group. 17 Recently, the successful treatment of psoriatic skin with topicallyapplied PTX has been described, 18 and the successful treatment of Schamberg's disease with PTX (300 mg daily) in four patients. A significant improvement was observed within 2-3 weeks. 19 Because of this rapidly growing list of diseases which benefit from treatment with PTX, it has been suggested that the medication might be designated as the 'drug of the decade'. 20 Understanding the mechanisms underlying its beneficial effects and those of other phosphodiesterase inhibitors in such a variety of skin diseases is important in defining the optimal conditions for application of these drugs. As the great majority of the clinical investigations and in vitro studies have been performed with PTX, the present paper will focus on the drug as a model for the effects of phosphodiesterase inhibitors in skin inflammation. Recent information regarding its biological effects on skin inflammation will also be discussed, and for that purpose, the development of skin inflammation is arbitrarily subdivided into four subsequent steps (Fig. 1 ).
PTX and pro-inflammatory cytokines
The initial event in many inflammatory skin diseases is the production of proinflammatory cytokines by epidermal and dermal cells induced by environmental challenges such as ultraviolet (UV) radiation, allergens, chemical irritants, tumour promoters and infections. 21 These stimuli can directly induce keratinocytes to produce and release pro-inflammatory cytokines, such as interleukin (IL)-1a, tumour necrosis factor (TNF)-a and IL-6. 21,22 PTX was initially described as inhibiting the liposaccharide (LPS)-induced production of TNF-a mRNA and protein by murine and human monocytes and macrophages. 11, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] This was shown to be modulated by an elevation of cAMP. 37, 38 Recently, Neuner et al. 39 further demonstrated in vivo and in vitro that PTX down-regulates intercellular adhesion molecule (ICAM)-1 expression on human monocytes mediated secondary to TNF-a suppression. PTX inhibited the UVB-induced production of TNF-a by keratinocytes. 40 It was then also found to inhibit the production of interferon (IFN)-g, IL-1, IL-6 and IL-8 by leukocytes 25, [27] [28] [29] [30] [31] [32] [33] [34] [35] and keratinocytes (IL-1, IL-6) . 40 By inhibiting the production of pro-inflammatory cytokines by keratinocytes and leukocytes, PTX is able to prevent or diminish the first step of the inflammatory process. Furthermore, PTX has been recently shown to up-regulate the anti-inflammatory cytokine IL-10 in monocytes through cAMP elevation.
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PTX and leukocyte/endothelial cell adhesion
Proinflammatory cytokines such as TNF-a, IL-1 and IFN-g have a strong inductive effect on the expression of adhesion molecules on endothelial cells, which leads to the adhesion of leukocytes to the endothelial cells and their subsequent transmigraton of leukocytes from the bloodstream into the site of inflammation. 42, 43 The inhibitory effect of PTX on the production of proinflammatory cytokines is likely to result in a decreased upregulation of adhesion molecules on endothelial cells, and in this way interfere with the extravasation of inflammatory cells. In addition, there is mounting evidence that PTX can also directly inhibit leukocyte/ endothelial cell binding. Previous studies showed that PTX inhibits the adhesion of neutrophils and monocytes to endothelial cells, [44] [45] [46] [47] a process in which cAMP was shown to be involved. 48 More recently, it was demonstrated that PTX, at therapeutic concentrations (10 -3 -10 -5 M), also inhibited the adhesion of T lymphoma cells to TNF-a-stimulated mouse endothelioma cells, 49 and the adhesion of human T cells to human dermal microvascular endothelial cells (HMEC-1) . 50 This inhibition is probably the result of a change in the activation state of the adhesion molecule LFA-1 on the T lymphocytes mediated by an increase in the intracellular cAMP-level induced by PTX 50 (Fig. 2) . Variable results were also found on the capacity of PTX to inhibit endothelial cell expression of ICAM-1, the ligand of lymphocyte function-associated antigen (LFA)-1, and the endothelial adhesion molecule VCAM-1. On the one hand, PTX was found to inhibit murine endothelial VCAM-1 expression, 51 while Weiss et al. 49 did not find an effect of PTX on either VCAM-1 or ICAM-1 expression.
PTX and chemokines
Chemokines are members of a recently described superfamily of cytokines, subdivided into C-C (RANTES, MCP) and C-X-C (IL-8, inducible protein (IP)-10) groups, with chemotactic, cell adhesion promoting and immune response-modulating properties. 52 Chemokines can be produced by many cell types, e.g. T lymphocytes, monocytes, endothelial cells and keratinocytes. [52] [53] [54] The C-X-C chemokine IL-8, produced by keratinocytes, is considered to play an important role in the infiltration of polymorphonuclear leukocytes in the epidermis in psoriasis. 55 Similarly, keratinocyte-derived IFN-ginduced IL-10 may be involved in the preferential influx of lymphocytes into the epidermis as observed in cutaneous T cell lymphoma. 56 Moreover, IP-10 was shown to potentiate T cell adhesion to endothelium. 57 It was shown that PTX inhibited IFN-g-induced IP-10 (g-IP-10) mRNA expression in cultured human keratinocytes in a dose-dependent way at pharmacological concentrations. 58 Variable results have been found on the effect of PTX on IL-8 production by peripheral blood mononuclear cells. [32] [33] [34] These studies suggest that PTX is also able to influence chemokine production, and in this way may interfere with the influx of inflammatory cells into the skin.
PTX and leukocyte/keratinocyte adhesion
After their transmigration and chemotaxis, leukocytes adhere to dermal and epidermal components like the extracellular matrix, dendritic cells and keratinocytes. Adhesion of leukocytes to other cells is an important step in skin inflammation. Previous studies have shown that T cell/keratinocyte adhesion induces the production of TNF-a, IL-6 and ICAM-1 mRNA by keratinocytes, 59 and forms an essential step in the stimulation of keratinocyte-induced T cell proliferation 60, 61 and T cell mediated cytotoxicity. 62 Recently, we found that PTX, at pharmacological concentrations (10 -3 -10 -5 M), inhibits such adhesion of T lymphocytes to keratinocytes in a dosedependent manner, probably also involving the above described effect of cAMP elevation on LFA-1 63 (Fig. 2) . In two separate studies no inhibiting effect of PTX on the expression of the LFA-1 ligand ICAM-1 was found in cultured monolayers of keratinocytes. However, when PTX was added to human skin biopsies in short-term organ culture, the LPS-and TNF-a-induced ICAM-1 expression of keratinocytes and Langerhans cells was indeed completely inhibited; 63, 64 thus far these discrepancies are unexplained.
PTX inhibits T lymphocyte/keratinocyte adhesion and thereby influences the effects of cell interactions. This can result in a reduction of cytokine release and inhibition of cell proliferation, and thus interfere with the amplification of skin inflammation. In addition, PTX may also affect T lymphocytes directly, PTX having been shown to inhibit T cell proliferation, 31 and the phytohaemagglutinin-induced production of IL-2 and IL-2 receptor expression in human peripheral blood mononuclear cells. 30, 31, 65 
Conclusions and perspectives
Clinical evidence has shown the potential therapeutic value of PTX in common inflammatory dermatoses, such as allergic contact hypersensitivity and psoriasis. 10, 17, 18 The mechanisms underlying these beneficial effects are now beginning to be understood. In vitro studies have shown the drug interferes with several steps of the inflammatory process and it has been shown to influence the production of proinflammatory cytokines in leukocytes and keratinocytes. Furthermore, it is able to inhibit leukocyte adhesion to endothelial cells and keratinocytes, and to decrease production of the chemokine g-IP-10, involved in the preferential infiltration of leukocytes in several skin diseases. Together, these effects could clearly lead to a down-regulation of the inflammatory process.
In conclusion, there is accumulating evidence that PTX, as well as related phosphodiesterase inhibitors, represent an extremely interesting group of anti-inflammatory agents with great potential in the treatment of inflammatory skin diseases; however, clinical evidence suggests that oral doses of PTX that are commonly used are not always sufficient to obtain tissue concentrations necessary for an effective anti-inflammatory effect. 66 Systemic use of higher doses of phosphodiesterase inhibitors is limited by side-effects. A highly potent and selective phosphodiesterase inhibitor, CP80,633, has recently been described by Hanifin et al.; 3 topical treatment of atopic dermatitis patients with it has resulted in significant clinical improvements and the reduction of inflammatory parameters. Furthermore, the successful topical application of PTX has also been described in nude mice grafted with psoriatic human skin with significant reductions in epidermal thickness. 18 Further examination of the more potent phosphodiesterase inhibitors for their anti-inflammatory effects in well-defined systems, and the development of such inhibitors that can be applied topically, is now expected to become a fruitful area of research.
